08/31/2026
Rapid advancement of treatment options for patients with cancer, such as the approval last week of Daraxonrasib (Rasonque) for metastatic pancreatic cancer, is providing hope for thousands. Identifying oncology practices who are proactively implementing education programs and developing their team to best treat patients with these new therapies is essential.
Dr. Mohamad Kassar, President of Northwest Cancer Centers discusses the ways his team worked to ensure they were prepared to immediately treat patients with this emerging therapy.
Exploring new pancreatic cancer treatments? Learn how Northwest Cancer Centers is preparing for daraxonrasib, KRAS-targeted therapy, molecular testing, and second opinions for patients in Northwest Indiana, Chicago, and Southwest Michigan.